Reforgene named a 2024 Future Healthcare Top 100 company for the second consecutive year
From May 7 to 10, 2024, the 8th VBEF Future Healthcare Ecosystem Exhibition was held at the Beiren Yichuang International Convention and Exhibition Center in Beijing. The conference, themed "New Youth", interpreted the pioneering spirit of healthcare innovation trailblazers. On the evening of May 9, the conference released the Future Healthcare Top 100 list. Guangzhou Reforgene Medicine Co., Ltd. ("Reforgene"), focused on innovative R&D of gene editing medicines, was again selected into the 2024 Future Healthcare Top 100, Innovative Medicine and Biologics TOP100, following 2023.
Receiving this honor consecutively shows that Reforgene's achievements in gene editing technology and drug innovation have been affirmed by industry experts, industry observers and analysis institutions. "New Youth" means passion, hope and mission, and responsibility, commitment and dreams. Reforgene continuously upholds the philosophy of innovation for life, is driven by gene editing technology, crosses uncharted territory, leads the wave of gene editing drug innovation, and provides accessible, curative medicines for more patients with serious diseases.
2024 Future Healthcare Top 100
Founded in 2015 by VB100, VBDATA and Danke Research Institute, the Future Healthcare Top 100 list is the first domestic list for innovative healthcare companies targeting non-listed enterprises. It aims to select Chinese innovative healthcare providers that truly represent the future of healthcare, discover the core strength of China's future healthcare industry, and promote the innovation and transformation of the health industry.
After eight years of practice and exploration, the "Future Healthcare Top 100" selection has received strong support and recognition from many investment institutions and enterprises, and has become an investment bellwether in the healthcare field, leading the development and investment trends of China's healthcare innovation now and for some time to come, providing reference for the subsequent financing of innovative enterprises.
About Reforgene
Reforgene Medicine is one of China's leading innovative gene editing drug companies, driven by gene editing technology and dedicated to bringing novel medicines to life. The company has pipeline programs across genetic diseases and complex diseases. Its innovative beta-thalassemia medicine has achieved globally leading clinical progress, and it achieved the world's first cure of an alpha-thalassemia patient.
Media Contact
info@reforgene.com
Forward-Looking Statements
Reports, articles and other content published on this website may contain forward-looking statements relating to Reforgene Medicine ("the Company") and the gene editing and biopharmaceutical industries. These statements may address, among other things, the Company's strategy, research and development, product pipeline and related progress, clinical research, regulatory submissions and approvals, manufacturing, supply and commercialization, collaborations and licensing, as well as industry trends, market size and technological developments. Forward-looking statements can often be identified by words such as "anticipate," "expect," "plan," "intend," "aim," "may," "will," "continue," or similar expressions. They reflect the views of the party making the statement, based on information available as of the date of publication and the expectations and assumptions then held, and are not statements of historical fact.
Statements made or provided by the Company represent the Company's views. Statements made or republished by third-party media, research institutions, experts or other parties represent only the views of those parties and do not necessarily represent the Company's position. Forward-looking statements are subject to known and unknown risks and uncertainties, including but not limited to those relating to research and technology, safety and efficacy, clinical trials, regulatory review and approval, manufacturing and supply, commercialization, collaborations and licensing, intellectual property, competition, laws and regulations, and macroeconomic conditions. Actual results, progress in research or commercialization, and the timing of events may differ materially from those expressed or implied by such statements. Readers should not place undue reliance on forward-looking statements, and past performance is not indicative of future results.
Except as required by law or regulatory requirements, the Company undertakes no obligation to update or revise any forward-looking statements made by it and gives no assurance that they will be realized. Third-party statements are the responsibility of their original publishers. This notice does not constitute investment advice or an offer or solicitation for the subscription, purchase or sale of any securities.